A recent study finds that the addition of rasagiline (marketed as Azilect) to the treatment regimen of individuals with Parkinson’s disease significantly enhances clinical outcomes. The study was ...

Tel Aviv-traded shares in Teva jumped 3.2 percent while Lundbeck was up 3.7 percent at 1336 GMT. Teva, the world's biggest maker of generic drugs, said it intends to submit these results to the ...

Teva has plenty of lawsuits on its plate, even after resolving a couple of big opioid cases, but now it's worked its way past another one. The drugmaker agreed to pay $54 million to settle a years-old ...

Dublin, June 24, 2019 (GLOBE NEWSWIRE) -- The "Global Market Report on Azilect (Teva/Lundbeck/Takeda) 2019" has been added to ResearchAndMarkets.com's offering. Report Coverage Azilect ...

The launch ceremony of Azilect, an innovative drug developed by Lundbeck in collaboration with Teva to treat Parkinson's disease (PD), was held in Shanghai recently. Azilect is a new and different MAO ...

DUBLIN--(BUSINESS WIRE)--The "Azilect" report has been added to Research and Markets' offering. Azilect (Teva) is a pure isomer of rasagiline and is the most recent selective irreversible monoamine ...